Scientific Sessions 2025  /  Shifting Paradigms in Lipid Management for ASCVD Risk  /  The ODYSSEY of Lipid Lowering: Navigating the Growing Array of Therapeutics for LDL-C Reduction
Logo

American Heart Association

  44
  0

Final ID:

The ODYSSEY of Lipid Lowering: Navigating the Growing Array of Therapeutics for LDL-C Reduction

  • Tokgozoglu, Lale  ( HACETTEPE UNIVERSITY , Ankara , Turkey )
    • Author Disclosures:
    Lale Tokgozoglu: DO have relevant financial relationships ; Consultant:abbott:Active (exists now) ; Speaker:Pfizer:Past (completed) ; Speaker:Sanofi:Active (exists now) ; Consultant:Novonordisk:Active (exists now) ; Consultant:Novartis:Active (exists now) ; Consultant:MSD:Active (exists now) ; Consultant:Menarini:Active (exists now) ; Consultant:Eli Lilly:Active (exists now) ; Consultant:Daiichi Sankyo:Active (exists now) ; Consultant:Bayer:Active (exists now) ; Speaker:Amarin:Past (completed) ; Consultant:Astra:Past (completed) ; Speaker:Amgen:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Shifting Paradigms in Lipid Management for ASCVD Risk

Saturday, 11/08/2025 , 01:30PM - 02:45PM

Main Event

More abstracts on this topic:
Case Presentation for Discussion

Grant Jelani

Efficacy and Safety of Enlicitide, an Oral PCSK9 Inhibitor, for Lowering LDL Cholesterol in Adults with or At-Risk for ASCVD: The Phase 3 CORALreef Lipids Trial

Navar Ann Marie, Mendizabal Geraldine, Nuez Llota Julio, Zhu Pengfei, Zhuo Min, Ballantyne Christie, Mikhailova Elina, Catapano Alberico, Banka Puja, Blom Dirk, Cadena Alberto, Kourpanidis Susan, Lepor Norman, Tsukamoto Kazuhisa

More abstracts from these authors:
How Low and How Fast Should We Go with LDL-Cholesterol?

Ray Kausik, Lloyd-jones Donald, Tokgozoglu Lale

Discussant: Lipoprotein a therapeutics, understanding the pipeline

Tokgozoglu Lale, Goldberg Anne

You have to be authorized to contact abstract author. Please, Login
Not Available